|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a, kappa|
|Immunogen||Lysate of the human histiocytic leukemia cell line U937|
|Storage buffer||tissue culture supernatant|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:40|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-12433 targets Topoisomerase II alpha in IHC (P) applications and shows reactivity with Human samples.
The MA5-12433 immunogen is lysate of the human histiocytic leukemia cell line U937.
Topo II alpha plays important roles in synthesis and transcription of DNA as well as chromosomal segregation during mitosis. It is reported to be a sensitive and specific marker of late S-, G2- and M-phases in transformed and developmentally regulated normal cellsTopo II alpha is also implicated in drug resistance of tumor cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
The Predictive and Prognostic Role of Topoisomerase II¿ and Tissue Inhibitor of Metalloproteinases 1 Expression in Locally Advanced Breast Carcinoma of Egyptian Patients Treated With Anthracycline-based Neoadjuvant Chemotherapy.
MA5-12433 was used in immunohistochemistry to determine the prognostic and predictive role of topoisomerase IIalpha and tissue inhibitor of metalloproteinases 1 in patient with locally advanced breast cancer after anthracycline-based neoadjuvant chemotherapy
|El Rebey HS,Aiad HA,Abulkheir IL,Asaad NY,El-Wahed MM,Abulkasem FM,Mahmoud SF||Applied immunohistochemistry and molecular morphology : AIMM (24:167)||2016|
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
MA5-12433 was used in immunohistochemistry to study tumor topoisomerase II alpha status as a marker of sensitivity to anthracycline-based neoadjuvant chemotherapy in breast cancer
|Nikolényi A,Sükösd F,Kaizer L,Csörgo E,Vörös A,Uhercsák G,Ormándi K,Lázár G,Thurzó L,Brodowicz T,Kahán Z||Oncology (80:269)||2011|
Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
MA5-12433 was used in immunohistochemistry to study the relationship between protein expression and recurrence of benign World Health Organization grade I meningioma
|Kärjä V,Sandell PJ,Kauppinen T,Alafuzoff I||Human pathology (41:199)||2010|
Expression of cyclin A and topoisomerase IIalpha of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival.
MA5-12433 was used in immunohistochemistry to investigate the prognostic value of cyclin A and D1 as well as topoisomerase II alpha in oligodendrogliomas
|Park SH,Suh YL||Histopathology (42:395)||2003|
One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
MA5-12433 was used in immunohistochemistry - paraffin section to determine of the effects of 1-year endocrine therapy in patients with breast cancer
|Rusz O,Vörös A,Varga Z,Kelemen G,Uhercsák G,Nikolényi A,Ormándi K,Simonka Z,Kahán Z||Pathology oncology research : POR (21:977)||2015|
Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
MA5-12433 was used in immunohistochemistry - paraffin section to correlate the major cell cycle stages (G1, S-G2, and G2-M) with melanoma development and progression
|Kiszner G,Wichmann B,Nemeth IB,Varga E,Meggyeshazi N,Teleki I,Balla P,Maros ME,Penksza K,Krenacs T||Virchows Archiv : an international journal of pathology (464:603)||2014|